This article has been updated to report the total amount of funding in the round.
NEW YORK (GenomeWeb News) – FluimediX today said that it has closed a round of financing intended to support further development of its NanoCycler platform.
The Taastrup, Denmark-based firm raised DKK 6 million ($1.1 million) in the round that was led by Seed Capital Denmark. In addition, existing shareholders participated in the round.
FluimediX is developing the NanoCycler, a fully-automated diagnostic platform for rapidly measuring genetic mutations in patients. According to the firm's website, the system can conduct near-patient DNA-based testing in less than 15 minutes, from sample to result.
The firm, which was founded in 2003 and has its offices at the Danish Technical Institute, said that the funds from this round of financing would be dedicated to developing a test for warfarin metabolism.